Sarah Chang, PhD, is Medical Strategy Lead at UCB, where she works on the thymidine kinase 2 deficiency (TK2d) program. TK2d is a rare, life-threatening mitochondrial disease caused by changes in the TK2 gene. Sarah focuses on helping doctors recognize TK2d earlier and improving the path to diagnosis, so patients can get the care they need as soon as possible. She believes that every person—no matter how rare their condition—deserves timely care, meaningful support, and hope for a better future.
Upcoming Expert Series Presentations
Expert Series: Understanding TK2d and the KYGEVVI Approval
January 23 @ 12:00 pm









